Lupin announced the approval of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg.
Lupin's alliance partner Concord Biotech (Concord) has received an approval for Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Myfortic Delayed Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.
Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg (RLD: Myfortic) had an annual sales of approximately USD 174 million in the U.S. (IQVIA MAT Sept ember 2019).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
